For more information about Prof Sir Mark Pepys FRS please click here.
University College London is a modern, outward-looking institution, committed to engaging with the major issues of our times. One of the world’s leading multidisciplinary universities, UCL today is a true academic powerhouse. UCL is among the world’s top universities, as reflected in performance in a range of rankings and tables. UCL’s home page can be found here.
UCL Business PLC is responsible for commercialising innovations arising from the research base at University College London, one of the UK’s leading research-led universities. UCL Business undertakes a broad range of knowledge transfer activities, covering the facilitation of consultancy and collaborative research engagements, through to technology transfer, company incubation and investment. More information on UCL Business can be found at www.uclb.com.
The Wolfson Drug Discovery Unit, directed by Prof Sir Mark Pepys is within the Centre for Amyloidosis and Acute Phase Proteins (see below). The Centre for Amyloidosis and Acute Phase Proteins, formerly directed by Prof Sir Mark Pepys and now by Prof Philip Hawkins, conducts world leading research in all aspects of the pentraxin family of plasma proteins, and in amyloidosis. Find out more about the Centre at www.ucl.ac.uk/amyloidosis.
The National Amyloidosis Centre (NAC) is the only centre in the UK specialising in amyloidosis. It is funded centrally by the NHS and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world’s leading centres for amyloid research. Find out more about the NAC here.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.